For instance, finerenone combined with SGLT2is may be considered for patients with concurrent CKD and T2DM; for patients with hypertension and T2DM, angiotensin receptor neprilysin inhibitors (ARNIs) combined with SGLT2is may be considered; for patients with obesity and T2DM, GLP-1 RAs combined with SGLT2is could be taken into consideration (Gevaert et al., 2022; Zawadzka et al., 2022). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.